Localized Oncolytic Virotherapy Overcomes Systemic Tumor Resistance to Immune Checkpoint Blockade Immunotherapy
Open accessThe DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Abstract
Preexisting lymphocytic infiltration of tumors is associated with superior prognostic outcomes in a variety of cancers. Recent studies also suggest that lymphocytic responses may identify patients more likely to benefit from therapies targeting immune checkpoints, suggesting that therapeutic efficacy of immune checkpoint blockade can be enhanced through strategies that induce tumor inflammation. To achieve this effect, we explored the immunotherapeutic potential of oncolytic Newcastle disease virus (NDV). We find that localized intratumoral therapy of B16 melanoma with NDV induces inflammatory responses, leading to lymphocytic infiltrates and antitumor effect in distant (nonvirally injected) tumors without distant virus spread. The inflammatory effect coincided with distant tumor infiltration with tumor-specific CD4(+) and CD8(+) T cells, which was dependent on the identity of the virus-injected tumor. Combination therapy with localized NDV and systemic CTLA-4 blockade led to rejection of preestablished distant tumors and protection from tumor rechallenge in poorly immunogenic tumor models, irrespective of tumor cell line sensitivity to NDV-mediated lysis. Therapeutic effect was associated with marked distant tumor infiltration with activated CD8(+) and CD4(+) effector but not regulatory T cells, and was dependent on CD8(+) cells, natural killer cells, and type I interferon. Our findings demonstrate that localized therapy with oncolytic NDV induces inflammatory immune infiltrates in distant tumors, making them susceptible to systemic therapy with immunomodulatory antibodies, which provides a strong rationale for investigation of such combination therapies in the clinic.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Therapeutic approaches include stimulating innate responses with microbial peptides or oncolytic viruses, which have previously been shown to enhance local and systemic antitumor immunity in combination with ICT and may be able to improve payload to enhance agonist signals (194)(195)(196).”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [196]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Self-citationSafety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Enhancement of Antitumor Immunity by CTLA-4 Blockade
Leach, D. R., Krummel, M. F., & Allison, J. P. (1996) · Science · doi:10.1126/science.271.5256.1734 · Cited by 3,955
Self-citationCurran, M. A., Montalvo, W., Yagita, H., & Allison, J. P. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0915174107 · Cited by 1,874 · cited 1×
“Scie effector to Treg ratios, which has been previously demonstrated to be a marker of a favorable immunological response to immunotherapy (29, 30).”
BackgroundSelf-citationSpranger, S., Spaapen, R. M., Zha, Y., Williams, J., Meng, Y., Ha, T. T., & Gajewski, T. F. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006504 · Cited by 1,677 · cited 3×
“Data from clinical trials identified preexisting tumor-infiltrating lymphocytes (TILs) and an immune-active tumor transcriptional profile as strong predictors of response to immunotherapy (6, 7), with type I interferon (IFN) emerging as an important pathway in CD8-mediated tumor rejection (8, 9).”
BackgroundRussell, S. J., Peng, K.-W., & Bell, J. C. (2012) · Nature Biotechnology · doi:10.1038/nbt.2287 · Cited by 1,428
Cell Type-Specific Involvement of RIG-I in Antiviral Response
Kato, H., Sato, S., Yoneyama, M., Yamamoto, M., Uematsu, S., Matsui, K., Tsujimura, T., Takeda, K., Fujita, T., Takeuchi, O., et al. (2005) · Immunity · doi:10.1016/j.immuni.2005.04.010 · Cited by 1,368 · cited 1×
“Here, to trigger immunogenic tumor cell death and an inflammatory response, we used nonpathogenic NDV, which, despite its relatively weak lytic activity, has been demonstrated to be a potent inducer of type I IFN and DC maturation (26, 27).”
Fuertes, M. B., Kacha, A. K., Kline, J., Woo, S.-R., Kranz, D. M., Murphy, K. M., & Gajewski, T. F. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20101159 · Cited by 1,192 · cited 4×
“The presence of TILs in tumors has been shown to be associatedwith type I IFN transcriptional profile, and additional studies demonstrated the critical role for type I IFN in CD8a DCmediated antigen cross-presentation and priming of tumor-specific CD8 T cells (8, 9).”
BackgroundResultInfluentialType I interferon is selectively required by dendritic cells for immune rejection of tumors
Diamond, M. S., Kinder, M., Matsushita, H., Mashayekhi, M., Dunn, G. P., Archambault, J. M., Lee, H., Arthur, C. D., White, J. M., Kalinke, U., et al. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20101158 · Cited by 1,081 · cited 4×
“The presence of TILs in tumors has been shown to be associatedwith type I IFN transcriptional profile, and additional studies demonstrated the critical role for type I IFN in CD8a DCmediated antigen cross-presentation and priming of tumor-specific CD8 T cells (8, 9).”
BackgroundResultInfluentialvan Elsas, A., Hurwitz, A. A., & Allison, J. P. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.190.3.355 · Cited by 1,020
Self-citationOverwijk, W. W., Theoret, M. R., Finkelstein, S. E., Surman, D. R., de Jong, L. A., Vyth-Dreese, F. A., Dellemijn, T. A., Antony, P. A., Spiess, P. J., Palmer, D. C., et al. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20030590 · Cited by 925
IL-35-mediated induction of a potent regulatory T cell population
Collison, L. W., Chaturvedi, V., Henderson, A. L., Giacomin, P. R., Guy, C., Bankoti, J., Finkelstein, D., Forbes, K., Workman, C. J., Brown, S. A., et al. (2010) · Nature Immunology · doi:10.1038/ni.1952 · Cited by 869
Tumor-specific Th17-polarized cells eradicate large established melanoma
Muranski, P., Boni, A., Antony, P. A., Cassard, L., Irvine, K. R., Kaiser, A., Paulos, C. M., Palmer, D. C., Touloukian, C. E., Ptak, K., et al. (2008) · Blood · doi:10.1182/blood-2007-11-120998 · Cited by 845 · cited 7×
“Bioluminescent imaging was used to measure the distribution and expansion kinetics of the adoptively transferred Trp1 cells.”
BackgroundInfluentialHeo, J., Reid, T., Ruo, L., Breitbach, C. J., Rose, S., Bloomston, M., Cho, M., Lim, H. Y., Chung, H. C., Kim, C. W., et al. (2013) · Nature Medicine · doi:10.1038/nm.3089 · Cited by 779
An immune-active tumor microenvironment favors clinical response to ipilimumab
Ji, R.-R., Chasalow, S. D., Wang, L., Hamid, O., Schmidt, H., Cogswell, J., Alaparthy, S., Berman, D., Jure-Kunkel, M., Siemers, N. O., et al. (2012) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-011-1172-6 · Cited by 775 · cited 3×
“Data from clinical trials identified preexisting tumor-infiltrating lymphocytes (TILs) and an immune-active tumor transcriptional profile as strong predictors of response to immunotherapy (6, 7), with type I interferon (IFN) emerging as an important pathway in CD8-mediated tumor rejection (8, 9).”
BackgroundQuezada, S. A. (2006) · Journal of Clinical Investigation · doi:10.1172/jci27745 · Cited by 700 · cited 1×
“Scie effector to Treg ratios, which has been previously demonstrated to be a marker of a favorable immunological response to immunotherapy (29, 30).”
BackgroundBiological behavior of malignant melanoma cells correlated to their survival in vivo.
Fidler, I. J. (1975) · PubMed · Cited by 599
Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans
Breitbach, C. J., Burke, J., Jonker, D., Stephenson, J., Haas, A. R., Chow, L. Q. M., Nieva, J., Hwang, T.-H., Moon, A., Patt, R., et al. (2011) · Nature · doi:10.1038/nature10358 · Cited by 551
Concomitant Tumor Immunity to a Poorly Immunogenic Melanoma Is Prevented by Regulatory T Cells
Turk, M. J., Guevara-Patiño, J. A., Rizzuto, G. A., Engelhorn, M. E., & Houghton, A. N. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20041130 · Cited by 540 · cited 1×
“For our studies, we chose a bilateral flank melanoma model with staggered implantation of tumors at a schedule that was previously demonstrated not to be affected by concomitant immunity (28).”
MethodHamid, O., Schmidt, H., Nissan, A., Ridolfi, L., Aamdal, S., Hansson, J., Guida, M., Hyams, D. M., Gómez, H., Bastholt, L., et al. (2011) · Journal of Translational Medicine · doi:10.1186/1479-5876-9-204 · Cited by 534 · cited 1×
“DISCUSSION The presence of TILs has been shown to be a favorable prognostic indicator in a number of cancers, and gene expression profiling demonstrated that patients with high baseline tumor expression of genes related toboth innate and adaptive immune response weremore likely to favorably respond to immunotherapy (7…”
BackgroundKaufman, H. L., Kim, D. W., DeRaffele, G., Mitcham, J., Coffin, R. S., & Kim-Schulze, S. (2010) · Annals of Surgical Oncology · doi:10.1245/s10434-009-0809-6 · Cited by 518
Depleting tumor-specific Tregs at a single site eradicates disseminated tumors
Marabelle, A., Kohrt, H., Sagiv-Barfi, I., Ajami, B., Axtell, R. C., Zhou, G., Rajapaksa, R., Green, M. R., Torchia, J., Brody, J., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci64859 · Cited by 386
Pecora, A. L., Rizvi, N., Cohen, G. I., Meropol, N. J., Sterman, D., Marshall, J. L., Goldberg, S., Gross, P., O’Neil, J. D., Groene, W. S., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.08.042 · Cited by 385
Type I IFN Contributes to NK Cell Homeostasis, Activation, and Antitumor Function
Swann, J. B., Hayakawa, Y., Zerafa, N., Sheehan, K. C. F., Scott, B., Schreiber, R. D., Hertzog, P., & Smyth, M. J. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.12.7540 · Cited by 339 · cited 1×
“Furthermore, the combination strategy was completely ineffective in IFNAR mice, which support the role of the type I IFNpathway in the induction of antitumor immunity in this system (8, 9, 36).”
BackgroundDepleting tumor-specific Tregs at a single site eradicates disseminated tumors
Marabelle, A., Kohrt, H., Sagiv-Barfi, I., Ajami, B., Axtell, R. C., Zhou, G., Rajapaksa, R., Green, M. R., Torchia, J., Brody, J., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci73340 · Cited by 307 · cited 1×
“Indeed, combination therapy using intratumoral CpG oligonucleotides with antibodies targeting immune checkpoints has been shown to be an effective therapeutic strategy resulting in depletion of Tregs at the injected tumor site and in regression of distant tumors (25).”
BackgroundFranciszkiewicz, K., Boissonnas, A., Boutet, M., Combadière, C., & Mami-Chouaib, F. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-2027 · Cited by 272
Oncolytic Newcastle Disease Virus for Cancer Therapy: Old Challenges and New Directions
Zamarin, D., & Palese, P. (2012) · Future Microbiology · doi:10.2217/fmb.12.4 · Cited by 254
Self-citationGajewski, T. F., Louahed, J., & Brichard, V. G. (2010) · The Cancer Journal · doi:10.1097/ppo.0b013e3181eacbd8 · Cited by 250
Fisher, D. T., Chen, Q., Skitzki, J. J., Muhitch, J. B., Zhou, L., Appenheimer, M. M., Vardam, T. D., Weis, E. L., Passanese, J., Wang, W.-C., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci44952 · Cited by 229
Characterization of the major histocompatibility complex class I deficiencies in B16 melanoma cells.
Seliger, B., Wollscheid, U., Momburg, F., Blankenstein, T. J. F., & Huber, C. (2001) · PubMed · Cited by 195
Schirrmacher, V., & Fournier, P. (2009) · Methods in molecular biology · doi:10.1007/978-1-59745-561-9_30 · Cited by 151
Cancer immunotherapy: co-stimulatory agonists and co-inhibitory antagonists
Peggs, K. S., Quezada, S. A., & Allison, J. P. (2009) · Clinical and Experimental Immunology · doi:10.1111/j.1365-2249.2009.03912.x · Cited by 141 · cited 1×
“INTRODUCTION The discovery of T cell regulatory receptors provided targets for immunotherapies aiming to enhance activation of antitumor immune responses or to reverse immunosuppressive mechanisms governing tumor resistance to immune surveillance and destruction (1).”
BackgroundSelf-citationAndtbacka, R. H. I., Collichio, F. A., AMATRUDA, T. T., Senzer, N. N., Chesney, J. A., Delman, K. A., S̄pitler, L. E., Puzanov, I. J., Doleman, S., Ye, Y., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.15_suppl.lba9008 · Cited by 119
Pulido, J. S., Kottke, T. J., Thompson, J., Galivo, F., Wongthida, P., Díaz, R. M., Rommelfanger, D. M., Ilett, E. J., Pease, L. R., Pandha, H., et al. (2012) · Nature Biotechnology · doi:10.1038/nbt.2157 · Cited by 117
Type I Interferon-Sensitive Recombinant Newcastle Disease Virus for Oncolytic Virotherapy
Elankumaran, S., Chavan, V., Qiao, D., Raghunath, S., Moorkanat, G., Biswas, M., & Samal, S. K. (2010) · Journal of Virology · doi:10.1128/jvi.01553-09 · Cited by 106
Schirrmacher, V. (2009) · International Journal of Oncology · doi:10.3892/ijo_00000223 · Cited by 105 · cited 1×
“Here, to trigger immunogenic tumor cell death and an inflammatory response, we used nonpathogenic NDV, which, despite its relatively weak lytic activity, has been demonstrated to be a potent inducer of type I IFN and DC maturation (26, 27).”
Zamarin, D., Martínez‐Sobrido, L., Kelly, K. J., Mansour, M., Sheng, G., Vigil, A., García‐Sastre, A., Palese, P., & Fong, Y. (2009) · Molecular Therapy · doi:10.1038/mt.2008.286 · Cited by 102 · cited 1×
“In our previous studies, we demonstrated that NDV induces type I IFN expression in B16-F10 cells (14).”
BackgroundSelf-citationT-cell priming in bone marrow: the potential for long-lasting protective anti-tumor immunity
Schirrmacher, V., Feuerer, M., Fournier, P., Ahlert, T., Umansky, V., & Beckhove, P. (2003) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2003.10.001 · Cited by 88
Selective oncolytic effect of an attenuated Newcastle disease virus (NDV-HUJ) in lung tumors
Yaacov, B., Elihaoo, E., lazar, I., Ben-Shlomo, M., Greenbaum, I., Panet, A., & Zakay-Rones, Z. (2008) · Cancer Gene Therapy · doi:10.1038/cgt.2008.31 · Cited by 69
Schirrmacher, V. (2011) · International Journal of Oncology · doi:10.3892/ijo.2011.1265 · Cited by 51 · cited 1×
“At present, it is unclear what contributes to the relative reduction in the number of Tregs, although NDV-induced inflammatory cytokines have been previously suggested to have functions that could counter Treg activity (31).”
BackgroundDezfouli, S., Hatzinisiriou, I., & Ralph, S. J. (2003) · Immunology and Cell Biology · doi:10.1046/j.0818-9641.2003.01189.x · Cited by 25
Role of Interferon in the Anti-Melanoma Effects of Poly (I).Poly (C) and Newcastle Disease Virus
Bart, R. S., Kopf, A. W., Vilček, J., & Lam, S. (1973) · Nature New Biology · doi:10.1038/newbio245229a0 · Cited by 14
Cited by
The future of immune checkpoint therapy
Sharma, P., & Allison, J. P. (2015) · Science · doi:10.1126/science.aaa8172 · Cited by 4,878
Self-citationInflammation and tumor progression: signaling pathways and targeted intervention
Zhao, H., Wu, L., Yan, G., Chen, Y., Zhou, M., Wu, Y., & Li, Y. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00658-5 · Cited by 2,792
Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential
Sharma, P., & Allison, J. P. (2015) · Cell · doi:10.1016/j.cell.2015.03.030 · Cited by 2,345
“Finally, CTLA-4 could be combined with local delivery of irradiation, cryoablation, or an oncolytic virus to induce systemic tumor immunity and eradication of distant metastases (Zamarin et al., 2014; Waitz et al., 2012; Tang et al., 2014).”
BackgroundSelf-citationChiappinelli, K. B., Strissel, P. L., Desrichard, A., Li, H., Henke, C., Akman, B., Hein, A., Rote, N. S., Cope, L. M., Snyder, A., et al. (2015) · Cell · doi:10.1016/j.cell.2015.07.011 · Cited by 2,022
“Finally, our drug approach to upregulate viral defense signaling might be compared to the use of oncolytic viruses to induce inflammatory immune infiltrates at tumor sites to sensitize to immunomodulation (Zamarin et al., 2014).”
Self-citationOncolytic viruses: a new class of immunotherapy drugs
Kaufman, H. L., Kohlhapp, F. J., & Zloza, A. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4663 · Cited by 1,642
“Preclinical studies have demonstrated the importance of tumour-specific CD8 + T cells in mediating tumour rejection with oncolytic viruses 13 .”
Background
Metadata
- Authors
- Zamarin, D., Holmgaard, R. B., Subudhi, S. K., Park, J. S., Mansour, M., Palese, P., Merghoub, T., Wolchok, J. D., & Allison, J. P.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- The University of Texas MD Anderson Cancer Center (US)
- Cornell University (US)
- Icahn School of Medicine at Mount Sinai (US)
- Corresponding author
- Zamarin, Dmitriy
- Wolchok, Jedd D.
- Allison, James P.
- ORCID
- Venue
- Science Translational Medicine
- Published
- 2014-03-05
- Volume
- 6
- Issue
- 226
- Pages
- 226ra32-226ra32
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- PMC
- PMC4106918
- OpenAlex
- W2170739773
- Cited by
- 711
- References
- 42
- Citations by year
- 2026: 26 · 2025: 29 · 2024: 30 · 2023: 54 · 2022: 53 · 2021: 79 · 2020: 82 · 2019: 71 · 2018: 67 · 2017: 74 · 2016: 54 · 2015: 67 · 2014: 23
- FWCI
- 47.60
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Howard Hughes Medical Institute
- National Cancer Institute (T32CA078207, R01CA056821, CA056821, P30CA008748, P30CA016672, T32CA009207, R25CA020449)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- oncolytic virotherapy, Newcastle disease virus, immune checkpoint blockade, CTLA-4 blockade, B16 melanoma, tumor inflammation, intratumoral injection, tumor-infiltrating lymphocytes, CD8+ T cells, CD4+ T cells, regulatory T cells, natural killer cells, type I interferon, combination immunotherapy, tumor rechallenge
- MeSH terms
- Animals, Immune System, Immunotherapy, Inflammation, Interferon Type I, Killer Cells, Natural, Lymphocytes, Melanoma, Experimental, Neoplasm Transplantation, Newcastle disease virus, CD4-Positive T-Lymphocytes, CD8-Positive T-Lymphocytes, Oncolytic Virotherapy, Oncolytic Viruses, Mice, CTLA-4 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.